Which fluoroquinolone antibiotic is classified as the 4th generation and is known for better coverage against resistant bacteria?

Besifloxacin is recognized as a fourth-generation fluoroquinolone antibiotic, distinguished by its enhanced coverage against resistant bacteria compared to earlier generations. This improved efficacy stems from its unique chemical structure, which allows for better binding to bacterial enzymes and greater activity against common ocular pathogens like Staphylococcus aureus and Streptococcus pneumoniae.

In addition to its broader spectrum of activity, besifloxacin is specifically formulated for ophthalmic use, making it particularly effective for treating bacterial conjunctivitis and other eye infections. Its lipophilic properties facilitate deeper penetration into ocular tissues, giving it an advantage in clinical settings where resistance to earlier generation fluoroquinolones is a significant concern.

Furthermore, besifloxacin has a lower propensity to cause resistance itself due to its mechanism of action. This characteristic is vital in the context of rising antibiotic resistance, allowing it to maintain effectiveness over time in the face of evolving bacterial strains.